ADC play SynAffix raises series A

SynAffix B.V. (Oss, the Netherlands) raised an undisclosed amount in a series A round from new investors Aravis; BioGeneration Ventures; MS Ventures, the strategic corporate fund of the Merck Serono division of Merck KGaA (Xetra:MRK); and BOM Capital. SynAffix is developing its GlycoConnect technology, which attaches a toxic payload to a glycoprotein without requiring prior engineering of the protein. The company said the technology creates stable and homogenous antibody-drug conjugates (ADCs). SynAffix has deals with undisclosed companies. ...